| Metric | Value |
| Company Name | Grifols, S.A. |
| Global Headquarters | Sant Cugat del Vallès, Barcelona, Spain |
| Year Founded | 1909 (Incorporated in 1987) |
| Chief Executive Officer | Nacho Abia |
| Non-Executive Chair | Anne-Catherine Berner |
| Total Net Revenue (2025) | €7,524 million |
| Gross Margin (2025) | €2,859 million |
| Reported EBITDA (2025) | €1,693 million |
| Operating Result / EBIT (2025) | €1,243 million |
| Consolidated Net Profit (2025) | €500 million |
| Total Assets (2025) | €19,712 million |
| Total Liabilities (2025) | €12,109 million |
| Total Equity (2025) | €7,603 million |
| Net Financial Debt | €7,759 million |
| Leverage Ratio | 4.2x |
| Research & Development Investment | €426 million |
| Global Plasma Donation Centers | Over 400 |
| Total Carbon Emissions (Scope 1 & 2) | 205,777 t CO2e |
| Total Global Workforce | 25,247 employees (implied) |
| Largest Revenue Segment | Biopharma (86.2% of Total Revenue) |
Company overview
Grifols, S.A. operates as a highly integrated and globally diversified healthcare conglomerate, distinctly specialized in the research, development, manufacturing, and commercialization of plasma-derived medicines (hemoderivatives). Functioning as a vital bridge between committed plasma donors and patients suffering from rare and chronic diseases, the organization stands as a worldwide leader in plasma therapies, transfusion medicine, and advanced diagnostic solutions.
The corporate purpose is unequivocally defined by the ambition to enhance global health, helping individuals live longer and healthier lives while amplifying positive societal impacts through a sustainable operational model. Grifols oversees the world’s largest private plasma-supply network, characterized by robust vertical integration. This comprehensive value chain begins with plasma procurement from hundreds of donation centers and culminates in the distribution of life-saving therapies across immunology, neurology, pulmonology, hematology, hepatology, and intensive care.
- Total net revenues reached €7,524 million for the fiscal year 2025.
- The company allocated €426 million directly to Research and Development (R&D) activities, representing approximately 6% of total income.
- Over the past five years, capital allocation toward R&D and innovation has surpassed €1,921 million.
Through its strategic operational hubs and advanced manufacturing facilities spanning North America and Europe, Grifols ensures the highest standards of safety, quality, and efficacy. The enterprise extends its impact beyond therapeutic treatments by maintaining a robust Diagnostics division that fortifies the safety of the global blood supply, alongside a Bio Supplies division that repurposes plasma materials for critical scientific research.
Business segments
Grifols is structurally organized into four primary business units that align with its diverse healthcare activities.
Plasma Procurement and Biopharma
This segment represents the core engine of the enterprise, concentrating entirely on activities related to the procurement of human plasma and the subsequent manufacturing and commercialization of plasma-derived medicines for therapeutic applications. The division oversees the global network of donation centers and the sophisticated fractionation and purification plants. The segment manages therapies addressing critical conditions in immunology, neurology, hematology, and intensive care.
- Revenue: €6,487 million
- Percentage of Total Revenue: 86.2%
- EBITDA: €1,746 million
Diagnostic
The Diagnostic division is dedicated to the marketing, development, and production of diagnostic testing equipment, reagents, and advanced automated analyzers. These solutions are pivotal in transfusion medicine, enabling the precise screening and typing of blood, plasma, and tissue donations to prevent disease transmission. The unit ensures compatibility between donors and recipients, thereby optimizing blood product inventories globally.
- Revenue: €640 million
- Percentage of Total Revenue: 8.5%
- EBITDA: €159 million
Others
This segment aggregates revenues derived from third-party manufacturing services (toll manufacturing/maquila), hospital management solutions, and the commercialization of specialized pharmaceutical products intended for hospital pharmacies. It additionally encompasses the group’s emerging research entities and collaborative technological initiatives.
- Revenue: €243 million
- Percentage of Total Revenue: 3.2%
- EBITDA: €(26) million
Bio Supplies
The Bio Supplies division commercializes biological products intended strictly for non-therapeutic use. A significant operational mandate of this segment involves repurposing plasma that is deemed unsuitable for therapeutic fractionation. This material is subsequently transformed into analytical reagents utilized extensively in scientific research and diagnostic testing.
- Revenue: €154 million
- Percentage of Total Revenue: 2.0%
- EBITDA: €49 million
History and evolution
The legacy of the enterprise began in 1909, rooted in a commitment to pioneering hematology and plasma science. Building upon generations of specialized medical research, Grifols, S.A. was formally incorporated as a public limited company in Spain on June 22, 1987. The subsequent decades marked a period of aggressive international expansion and operational scaling.
Strategic acquisitions have continuously shaped the organization’s trajectory. In 2011, the acquisition of Talecris (Grifols Therapeutics) dramatically expanded the company’s footprint and plasma collection capacity in the United States. In 2014, the integration of Novartis’ Diagnostic business unit fortified Grifols’ leadership in transfusion medicine. In 2018, the enterprise expanded its European presence through the acquisition of Haema and BPC Plasma.
A monumental strategic milestone was achieved in 2022 when Grifols finalized a major investment in Biotest AG, creating powerful synergies to expand patient access to cutting-edge plasma therapies. In 2024, the enterprise successfully executed the sale of a 20% equity interest in Shanghai RAAS for €1,564 million, optimizing its capital structure. Moving into 2025, Grifols secured complete control over 14 strategic plasma collection centers in the U.S. previously managed under a joint venture with Immunotek, and acquired a 50.10% controlling stake in Canadian Plasma Resources Corporation, cementing its dominance in global plasma procurement.
Products and services
Grifols develops a critical portfolio of essential medicines, diagnostic tools, and biological materials.
Haemoderivatives / Plasma-derived medications
This product category encompasses all fractionated plasma proteins designed for therapeutic administration. The portfolio addresses chronic and acute conditions, featuring Immunoglobulins (for primary and secondary immunodeficiencies and neurological conditions), Alpha-1 antitrypsin, Albumin (utilized for liver cirrhosis and intensive care), Coagulation factors (for Hemophilia and Von Willebrand disease), and Fibrinogen.
- Revenue: €6,487 million
- Percentage of Total Revenue: 86.2%
Transfusional medicine
This service and product line provides comprehensive diagnostic solutions that guarantee the safety of the global blood supply. It includes advanced blood typing tests, viral screening platforms for blood and plasma donations, and state-of-the-art manual and automated laboratory analyzers.
- Revenue: €623 million
- Percentage of Total Revenue: 8.3%
Specialty pharmaceuticals & Third-party manufacturing
Products manufactured by the group tailored for hospital pharmacies, alongside toll manufacturing services where Grifols processes customer-owned plasma into finished therapies.
- Revenue: €243 million
- Percentage of Total Revenue: 3.2%
Biological materials for research (Bio Supplies)
Non-therapeutic biological products and repurposed plasma sold to external manufacturers for the creation of in vitro diagnostics and scientific research applications.
- Revenue: €154 million
- Percentage of Total Revenue: 2.0%
Other diagnostic
Clinical diagnostic solutions and specific recombinant antibody tools.
- Revenue: €17 million
- Percentage of Total Revenue: 0.2%
Brand portfolio
While the financial statements consolidate revenue at the category level, Grifols commands a portfolio of globally recognized proprietary brands that drive the therapeutic and diagnostic markets.
Gamunex / Flebogamma / Yimmugo
These flagship brands represent Grifols’ intravenous immunoglobulin franchise. They are critical therapies utilized by patients suffering from primary immunodeficiencies (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), and immune thrombocytopenia.
Prolastin
Prolastin is the enterprise’s premier Alpha-1 antitrypsin therapy, administered to patients with Alpha-1 antitrypsin deficiency to slow the progression of severe pulmonary conditions.
Procleix System
A cornerstone of the Diagnostics division, the Procleix system utilizes Nucleic Acid Testing (NAT) to screen blood and plasma donations for infectious pathogens, including HIV, Hepatitis B, Hepatitis C, and West Nile Virus. Recent innovations include the Procleix UltrioPlex W and Procleix Plasmodium assays.
DG Gel
The DG Gel brand encompasses Grifols’ proprietary blood typing cards and solutions, utilizing column agglutination technology to deliver precise pre-transfusion compatibility testing.
Tavlesse
A specialized non-plasma therapeutic brand focused on the treatment of chronic immune thrombocytopenia in adult patients.
Geographical presence
Grifols strategically organizes its operational and commercial footprint into four distinct geographical regions, ensuring a resilient and diversified global supply chain.
United States of America and Canada
This region represents the financial and operational nucleus of the enterprise. It houses the vast majority of the company’s plasma donation network (310 centers in the U.S. and an expanding presence in Canada). Major manufacturing and logistics hubs are situated in Los Angeles (California), Clayton (North Carolina), Emeryville (California), San Diego (California), and Montreal (Canada).
- Regional Revenue: €4,253 million
- Percentage of Total Revenue: 56.5%
- Assets Located in Region: €10,673 million
Rest of the world (RoW)
Encompassing dynamic markets across Asia, Latin America, and the Middle East, this segment is critical for international growth. It includes a joint venture operation managing 16 plasma centers in Egypt (Grifols Egypt for Plasma Derivatives S.A.E.) aimed at building regional self-sufficiency.
- Regional Revenue: €1,657 million
- Percentage of Total Revenue: 22.0%
- Assets Located in Region: €457 million
Rest of the European Union
A vital region featuring 97 plasma donation centers across several European nations. It hosts critical manufacturing infrastructure, most notably the Biotest facilities in Dreieich, Germany, and advanced logistics and packaging operations in Dublin, Ireland.
- Regional Revenue: €1,196 million
- Percentage of Total Revenue: 15.9%
- Assets Located in Region: €6,943 million
Spain
The foundational home of the enterprise. Spain hosts the corporate headquarters in Sant Cugat del Vallès, alongside major advanced manufacturing and fractionation facilities located in Parets del Vallès (Barcelona) and Torres de Cotilla (Murcia).
- Regional Revenue: €418 million
- Percentage of Total Revenue: 5.6%
- Assets Located in Region: €1,639 million
Profit and loss
| Consolidated Statements of Profit and Loss (Millions of Euros) | 2025 | 2024 |
| Net revenue | 7,524 | 7,212 |
| Cost of sales | (4,665) | (4,418) |
| Gross Margin | 2,859 | 2,794 |
| Research and development | (426) | (384) |
| Selling, general and administration expenses | (1,183) | (1,255) |
| Operating Expenses | (1,609) | (1,639) |
| Other income | 1 | 3 |
| Profit of equity accounted investees | (8) | 37 |
| Operating Result | 1,243 | 1,192 |
| Finance income | 34 | 44 |
| Finance costs | (625) | (714) |
| Dividends | 2 | 2 |
| Financial cost of sale of trade receivables | (14) | (31) |
| Change in fair value of financial instruments | 33 | 20 |
| Impairment of financial assets | (3) | (9) |
| Exchange differences | (55) | (60) |
| Finance result | (628) | (748) |
| Profit before income tax | 615 | 444 |
| Income tax expense | (115) | (231) |
| Consolidated net profit | 500 | 213 |
| Profit attributable to the Parent | 402 | 157 |
| Profit attributable to non-controlling interest | 98 | 56 |
- Gross Margin stood at €2,859 million, representing 38.0% of net revenues in 2025.
- Operating Result (EBIT) increased to €1,243 million.
- Total reported EBITDA for 2025 was €1,693 million.
Balance sheet
| Consolidated Balance Sheet – Assets (Millions of Euros) | 31/12/2025 | 31/12/2024 |
| Goodwill | 6,833 | 7,403 |
| Other intangible assets | 2,728 | 2,926 |
| Rights of use | 932 | 968 |
| Property, plant and equipment | 3,120 | 3,342 |
| Investment in equity-accounted investees | 97 | 69 |
| Non-current financial assets measured at fair value | 339 | 423 |
| Non-current financial assets at amortized cost | 173 | 67 |
| Total non-current financial assets | 512 | 490 |
| Deferred tax assets | 416 | 342 |
| Total non-current assets | 14,638 | 15,677 |
| Inventories | 3,296 | 3,560 |
| Current contract assets | 83 | 36 |
| Trade receivables | 651 | 705 |
| Other receivables | 101 | 78 |
| Current income tax assets | 17 | 53 |
| Total current financial assets | 36 | 244 |
| Other current assets | 65 | 72 |
| Cash and cash equivalents | 825 | 980 |
| Total current assets | 5,074 | 5,728 |
| Total assets | 19,712 | 21,405 |
| Consolidated Balance Sheet – Equity & Liabilities (Millions of Euros) | 31/12/2025 | 31/12/2024 |
| Share capital | 120 | 120 |
| Share premium | 911 | 911 |
| Reserves | 4,185 | 4,054 |
| Interim dividend | (102) | – |
| Treasury stock | (131) | (135) |
| Profit attributable to the Parent | 402 | 157 |
| Total Other comprehensive expenses | (114) | 776 |
| Equity attributable to the Parent | 5,271 | 5,883 |
| Non-controlling interests | 2,332 | 2,723 |
| Total equity | 7,603 | 8,606 |
| Non-current financial liabilities | 9,091 | 9,491 |
| Deferred tax liabilities | 861 | 1,012 |
| Total non-current liabilities | 10,090 | 10,643 |
| Current other financial liabilities | 552 | 676 |
| Suppliers | 841 | 852 |
| Other payables | 252 | 210 |
| Total trade and other payables | 1,118 | 1,123 |
| Total current liabilities | 2,019 | 2,156 |
| Total liabilities | 12,109 | 12,799 |
| Total equity and liabilities | 19,712 | 21,405 |
- Total Assets decreased from €21,405 million in 2024 to €19,712 million in 2025.
- Net Financial Debt stood at €7,759 million (excluding IFRS 16), resulting in a Leverage Ratio of 4.2x.
Cash flow
| Consolidated Statements of Cash Flow (Millions of Euros) | 2025 | 2024 |
| Profit before income tax | 615 | 444 |
| Amortization and depreciation | 450 | 438 |
| Finance cost/(income) | 828 | 681 |
| Change in inventories | 197 | 26 |
| Interest paid | (685) | (747) |
| Income tax paid | (169) | (176) |
| Net cash from/(used in) operating activities | 1,047 | 902 |
| Payments for investments | (108) | (286) |
| Property, plant and equipment | (265) | (233) |
| Intangible assets | (158) | (139) |
| Proceeds from the sale of investments | 9 | 1,588 |
| Net cash (used in) investing activities | (579) | 886 |
| Issue of financial liability instruments | 1,360 | 4,007 |
| Redemption and repayment | (1,550) | (5,248) |
| Lease payments | (119) | (111) |
| Dividends paid | (128) | (1) |
| Net cash from/(used in) financing activities | (529) | (1,359) |
| Effect of exchange rate fluctuations on cash | 94 | 22 |
| Net increase/ (decrease) in cash and cash equivalents | (155) | 451 |
| Cash and cash equivalents at year end | 825 | 980 |
- Net cash generated from operating activities amounted to a robust €1,047 million.
- Capital expenditures directed toward property, plant, and equipment reached €265 million.
Board of directors and leadership team
Grifols maintains a sophisticated corporate governance structure designed to ensure transparent and responsible management. Following recent strategic restructuring to separate ownership from daily operations, executive functions have been entirely consolidated under the Chief Executive Officer.
- Anne-Catherine Berner: Non-Executive Chair of the Board. Also serves on the Sustainability, Communication and Reputation Committee and the Strategy Committee.
- Nacho Abia: Chief Executive Officer (CEO). He is the sole board member with executive functions, responsible for the overarching operational management and strategic execution of the enterprise.
- Raimon Grifols Roura: Proprietary Director and Vice Chair. Contributes as a Member of the Sustainability, Communication and Reputation Committee and the Strategy Committee.
- Víctor Grifols Deu: Proprietary Director. Sits on the Appointments and Remuneration Committee and the Strategy Committee.
- Albert Grifols Coma-Cros: Proprietary Director. Member of the Sustainability, Communication and Reputation Committee.
- Tomás Dagá Gelabert: Director (Other External). Member of the Appointments and Remuneration Committee and the Strategy Committee.
- Enriqueta Felip Font: Independent Director. Member of the Sustainability, Communication and Reputation Committee.
- Susana González Rodríguez: Independent Director. Serves on the Appointments and Remuneration Committee and the Sustainability, Communication and Reputation Committee.
- Montserrat Muñoz Abellana: Independent Director. Member of the Audit Committee and the Appointments and Remuneration Committee.
- Íñigo Sánchez-Asiaín Mardones: Independent Director. Acts as a Member of the Audit Committee and the Strategy Committee.
- Pascal Ravery: Independent Director. Member of the Audit Committee.
- Paul S. Herendeen: Proprietary Director. Member of the Appointments and Remuneration Committee.
- Laura de la Cruz Galán: Deputy Secretary of the Board (Non-Director).
- Nuria Martín Barnés: Secretary of the Board (Non-Director).
- Víctor Grifols Roura: Serves honorarily as Honorary President Non-Director.
Subsidiaries, associates, joint ventures
The consolidated group comprises a vast network of fully controlled entities and strategic associates that facilitate its vertically integrated operations.
- Grifols Therapeutics, LLC (USA): 100% owned subsidiary operating within the Biopharma segment. Instrumental in plasma fractioning and the production of hemoderivatives.
- Biotest AG (Germany): 99.25% owned (Full consolidation). A transformative acquisition executed to accelerate plasma therapies, heavily contributing to the Biopharma segment’s revenue and R&D pipeline.
- Grifols Diagnostic Solutions, Inc. (USA): 55% owned. A pivotal subsidiary overseeing the manufacture and global commercialization of advanced blood testing products and diagnostic systems.
- Biomat USA, Inc. (USA): 80% owned. Responsible for the critical infrastructure required to procure human plasma across the United States.
- Biomat Holdings LLC (USA): 100% owned. Following a multi-stage acquisition finalized in early 2025, Grifols dissolved the Biotek America LLC joint venture with Immunotek, assuming 100% control and management of 28 plasma collection centers.
- Grifols Canada Plasma, Inc. (Canada): 50.10% ownership. Accounted for using the equity method, this associate operates plasma collection centers in Canada to secure vital raw materials.
- Grifols Egypt for Plasma Derivatives S.A.E. (Egypt): 49.00% ownership. A strategic equity-accounted joint venture with the Egyptian government dedicated to building plasma self-sufficiency through the construction of 20 collection centers and advanced fractionation facilities.
Other Investments (Including Minority / Portfolio Holdings)
Grifols strategically allocates capital to minority holdings that provide access to adjacent technologies and lucrative geographic markets.
- Shanghai RAAS Blood Products Co., Ltd. (China): 6.58% ownership. Classified as a financial asset measured at fair value through Other Comprehensive Income (OCI). Following the divestment of a 20% stake in 2024, Grifols retains this passive equity position, maintaining a fair value of €336 million as of December 31, 2025. It ensures continued alignment within the robust Chinese plasma market.
- BioDarou P.J.S. Co. (Iran): 39.40% ownership. An equity-accounted associate operating within the plasma derivatives sector.
- Mecwins, S.A. (Spain): 24.59% ownership. A strategic investment in a nanotechnology spin-off specializing in the development of ultrasensitive optical reading immunoassay technology for advanced diagnostic and prognostic applications.
Physical properties (offices, plants, factories, etc.)
Grifols requires a highly specialized, capital-intensive infrastructure to securely extract, transport, fractionate, and purify biological materials.
- Spain: The corporate headquarters is anchored in Sant Cugat del Vallès, Barcelona. The primary Spanish industrial hubs are situated in Parets del Vallès (Barcelona) and Torres de Cotilla (Murcia), focusing on large-scale plasma fractionation and the manufacturing of diagnostic equipment.
- United States: The U.S. operates as the core industrial nexus, housing advanced manufacturing facilities in Los Angeles (California), Clayton (North Carolina), Emeryville (California), and San Diego (California). Major logistical support and storage centers are localized in Memphis (Tennessee).
- Canada: Features a sophisticated immunoglobulin purification plant located in Montreal.
- Ireland: Advanced manufacturing, packaging, and global logistics facilities are operational in Dublin.
- Germany: The Biotest AG headquarters and primary manufacturing facilities are located in Dreieich, acting as a crucial European production node.
- Global Plasma Network: The enterprise manages a physical footprint of over 400 plasma donation centers globally.
- As of December 2025, Property, Plant, and Equipment carried a net book value of €3,120 million.
Founders
Grifols was built upon the scientific legacy of the Grifols family, which initiated its pioneering work in hematology and clinical analysis in 1909. Over four generations, the founding family has guided the transformation of a specialized laboratory into a global healthcare powerhouse. The family’s enduring influence is currently represented by Víctor Grifols Roura, who serves as the Honorary President Non-Director.
Parent
Grifols, S.A. operates as the ultimate parent company of the consolidated group. Incorporated in Spain on June 22, 1987, the parent entity coordinates administration, strategic management, and financial control over its vast portfolio of global subsidiaries and specialized business units.
Investments and capital expenditure plans
The organization exercises rigorous financial discipline while actively reinvesting in its productive capacity and scientific future.
- Capital Expenditures (CAPEX): In 2025, total capital expenditure reached €373 million. A significant portion of this allocation (€286 million) was directed toward expanding and upgrading Property, Plant, and Equipment, notably the expansion of the immunoglobulin purification infrastructure in Montreal and the continual upgrading of plasma center networks.
- Research and Development: R&D spending totaled €426 million in 2025. Grifols channels capital into both plasma therapies (e.g., advancing Fibrinogen and Trimodulin through Biotest) and revolutionary non-plasma innovations developed by subsidiaries like GigaGen and Alkahest.
- Environmental Capital Allocation: Recognizing its environmental responsibilities, Grifols directed €67 million toward environmental assets aimed at optimizing water consumption, enhancing wastewater treatment, and deploying renewable energy infrastructures to advance its decarbonization mandates.
Shareholding pattern
Grifols maintains a diverse shareholder base distributed across global institutional investors and the founding family.
- Floating Capital: 56.31%
- Related Shareholders and Board of Directors: 31.03%
- Blackrock: 4.28%
- Mason Capital: 3.17%
- Flat Footed: 3.13%
- Armistice Capital Master Fund: 1.06%
- Treasury Stock: 1.02%
Future strategy
Grifols’ forward-looking strategy relies on a framework of financial discipline, operational excellence, and targeted innovation.
Management has clearly articulated plans to guarantee and diversify the plasma supply chain while maximizing the operational efficiency of existing donation centers. Deleveraging remains a top strategic priority; the company is highly focused on reducing its net financial debt through rigorous cost controls and the maximization of free cash flow generation.
On the commercial front, Grifols is prioritizing the launch of differentiated products and the expansion of key therapies across new geographic markets. The enterprise aggressively pursues open innovation and digital transformation, seeking to integrate artificial intelligence (AI) across quality control and R&D pipelines to accelerate time-to-market for novel treatments. Furthermore, the company aligns its business growth directly with the Grifols 2030 Agenda, heavily emphasizing decarbonization and sustainable corporate governance.
Key strengths
- Unmatched Vertical Integration: Grifols controls the entirety of its supply chain, from operating the world’s largest private network of over 400 plasma collection centers to managing highly specialized fractionation facilities, ensuring absolute quality control and supply security.
- Diversified Business Model: While Biopharma acts as the revenue engine, the strong performance of the Diagnostic and Bio Supplies segments provides vital revenue diversification and cross-selling synergies.
- Robust Innovation Pipeline: A formidable R&D apparatus—fueled by an investment of €426 million in 2025—drives the continuous discovery of both plasma-derived therapies and advanced non-plasma treatments through specialized subsidiaries.
- Global Operational Footprint: A vast geographical presence anchors revenue streams, with the U.S. and Canada generating 56.5% of income, fortified by rapidly growing markets in Europe and the Rest of the World.
Key challenges and risks
- Financial Leverage: The organization carries a significant debt burden, reporting Net Financial Debt of €7,759 million and a leverage ratio of 4.2x in 2025. This structural reality makes the company sensitive to macroeconomic interest rate environments and necessitates strict capital discipline.
- Regulatory Complexity: Operating within the critical healthcare sector exposes Grifols to stringent, ever-evolving regulations mandated by the FDA, EMA, and local authorities. Any compliance failure could result in severe operational disruptions.
- Raw Material Dependency: The business is inherently reliant on the sustained, uninterrupted collection of human plasma. External shocks to donor availability or logistical networks present significant operational vulnerabilities.
- Competitive and Technological Disruption: The emergence of novel, non-plasma-based therapies by competitors targeting similar immunological and neurological conditions poses a constant threat, demanding relentless innovation and adaptation by Grifols.
Conclusion and strategic outlook
Grifols stands as a resilient, globally dominant force in the healthcare sector. By successfully navigating the complexities of post-pandemic supply chain recoveries, the enterprise has demonstrated a robust capacity to generate substantial operating cash flows and strong EBITDA margins. The strategic integration of recent acquisitions, notably Biotest AG and the U.S. Immunotek centers, firmly solidifies its unmatched infrastructure. Guided by a refined, independent governance structure and an unyielding commitment to scientific innovation and debt reduction, Grifols is optimally positioned to maintain its leadership in plasma therapies and transfusion medicine while driving sustainable, long-term value for patients, donors, and shareholders alike.
FAQ section
What are the primary business activities of Grifols? Grifols develops, manufactures, and commercializes plasma-derived medicines, diagnostic solutions for transfusion medicine, and biological materials for scientific research.
How much revenue did Grifols generate in 2025? Grifols reported a total net revenue of €7,524 million for the fiscal year 2025.
What is Grifols’ largest business segment? The Biopharma segment is the largest, generating €6,487 million in 2025, which accounts for 86.2% of the company’s total revenue.
Where is Grifols headquartered? The corporate headquarters is located in Sant Cugat del Vallès, Barcelona, Spain.
How many plasma donation centers does Grifols operate? Grifols operates the world’s largest private plasma-supply network, with over 400 donation centers located primarily in the U.S., Europe, and Egypt.
How much does Grifols invest in Research and Development? In 2025, Grifols invested €426 million in R&D, representing approximately 6% of its total revenue.
Who is the Chief Executive Officer of Grifols? Nacho Abia serves as the Chief Executive Officer of the company.
Official Site: https://www.grifols.com/
Source: Content on FirmsWorld.com is based on publicly available corporate filings, regulatory disclosures, annual reports, SEC 10-K filings, investor relations materials, and, where applicable, direct communications with the company.
